FREZENT
Frezent Biological Solutions is dedicated to eliminating the threat of recurrent cancer by developing innovative therapies that target dormant cancer cells. Their mission is to extend the lives of people with advanced stage cancer through novel antibody engineering and drug development, aiming for long-lasting remission for all cancer patients.
Industries
Nr. of Employees
small (1-50)
Products
Bifunctional Therapeutic Modalities
Therapeutic agents designed to target non-dividing, dormant cancer cells by blocking essential metabolic programs, preventing their transformation into recurrent cancer.
Bispecific Antibodies
Antibodies engineered to bind to two different antigens, used to target and neutralize dormant cancer cells.
Antibody-Drug Conjugates
Therapeutic compounds that combine antibodies with cytotoxic drugs to specifically target and kill dormant cancer cells.
Bifunctional Therapeutic Modalities
Therapeutic agents designed to target non-dividing, dormant cancer cells by blocking essential metabolic programs, preventing their transformation into recurrent cancer.
Bispecific Antibodies
Antibodies engineered to bind to two different antigens, used to target and neutralize dormant cancer cells.
Antibody-Drug Conjugates
Therapeutic compounds that combine antibodies with cytotoxic drugs to specifically target and kill dormant cancer cells.
Services
Initiate and develop collaborative research relationships, co-development projects, and funding partnerships focused on antibody therapeutics and preclinical development.
Initiate and develop collaborative research relationships, co-development projects, and funding partnerships focused on antibody therapeutics and preclinical development.
Expertise Areas
- Therapeutic antibody development
- Bispecific antibodies and antibody–drug conjugates
- Immuno-oncology
- Preclinical in vivo studies and imaging
Key Technologies
- Bispecific antibody formats
- Antibody–drug conjugates (ADCs)
- Antibody discovery and engineering
- Chemically modified DNA aptamers